JP2009516697A5 - - Google Patents

Download PDF

Info

Publication number
JP2009516697A5
JP2009516697A5 JP2008541463A JP2008541463A JP2009516697A5 JP 2009516697 A5 JP2009516697 A5 JP 2009516697A5 JP 2008541463 A JP2008541463 A JP 2008541463A JP 2008541463 A JP2008541463 A JP 2008541463A JP 2009516697 A5 JP2009516697 A5 JP 2009516697A5
Authority
JP
Japan
Prior art keywords
group
alkyl
optionally substituted
hydrogen
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2008541463A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009516697A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/060911 external-priority patent/WO2007092095A2/en
Publication of JP2009516697A publication Critical patent/JP2009516697A/ja
Publication of JP2009516697A5 publication Critical patent/JP2009516697A5/ja
Ceased legal-status Critical Current

Links

JP2008541463A 2005-11-18 2006-11-15 癌および炎症性疾患の治療のためのikk−ベータ阻害剤としての[4−(ベンゾ[b]チオフェン−2−イル)ピリミジン−2イル]アミン誘導体 Ceased JP2009516697A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73809705P 2005-11-18 2005-11-18
PCT/US2006/060911 WO2007092095A2 (en) 2005-11-18 2006-11-15 [4-(benzo [b] thi0phen-2-yl) pyrimidin-2yl] -amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases.

Publications (2)

Publication Number Publication Date
JP2009516697A JP2009516697A (ja) 2009-04-23
JP2009516697A5 true JP2009516697A5 (enExample) 2009-12-17

Family

ID=38345605

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008541463A Ceased JP2009516697A (ja) 2005-11-18 2006-11-15 癌および炎症性疾患の治療のためのikk−ベータ阻害剤としての[4−(ベンゾ[b]チオフェン−2−イル)ピリミジン−2イル]アミン誘導体

Country Status (27)

Country Link
US (1) US7547691B2 (enExample)
EP (1) EP1989200B1 (enExample)
JP (1) JP2009516697A (enExample)
KR (1) KR100990771B1 (enExample)
CN (1) CN101309918B (enExample)
AR (1) AR057911A1 (enExample)
AT (1) ATE437873T1 (enExample)
AU (1) AU2006337626B2 (enExample)
BR (1) BRPI0618245A2 (enExample)
CA (1) CA2629336A1 (enExample)
CR (1) CR9947A (enExample)
DE (1) DE602006008187D1 (enExample)
DK (1) DK1989200T3 (enExample)
EA (1) EA014426B1 (enExample)
EC (1) ECSP088456A (enExample)
ES (1) ES2329085T3 (enExample)
IL (1) IL190489A0 (enExample)
MA (1) MA30053B1 (enExample)
NO (1) NO20082594L (enExample)
PE (1) PE20070833A1 (enExample)
PL (1) PL1989200T3 (enExample)
PT (1) PT1989200E (enExample)
SI (1) SI1989200T1 (enExample)
TN (1) TNSN08227A1 (enExample)
TW (1) TW200800201A (enExample)
WO (1) WO2007092095A2 (enExample)
ZA (1) ZA200803940B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5066175B2 (ja) 2006-03-31 2012-11-07 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh4受容体のモジュレーターとしてのベンゾイミダゾール−2−イルピリミジンおよびピラジン
CA2658764A1 (en) * 2006-07-20 2008-01-24 Mehmet Kahraman Benzothiophene inhibitors of rho kinase
EA016178B1 (ru) 2006-12-21 2012-02-28 Эли Лилли Энд Компани Соединения имидазолидинониламинопиримидина
ATE479680T1 (de) 2006-12-21 2010-09-15 Lilly Co Eli Imidazolidinonylaminopyrimidinverbindungen zur behandlung von krebs
EP2155735A2 (en) 2007-05-16 2010-02-24 Eli Lilly And Company Triazolyl aminopyrimidine compounds
TW200908981A (en) 2007-05-16 2009-03-01 Lilly Co Eli Triazolyl aminopyrimidine compounds
US9371311B2 (en) 2008-06-30 2016-06-21 Janssen Pharmaceutica Nv Benzoimidazol-2-yl pyrimidine derivatives
TW201433568A (zh) 2008-06-30 2014-09-01 Janssen Pharmaceutica Nv 製備經取代之嘧啶衍生物的方法
KR101123178B1 (ko) * 2009-04-09 2012-06-13 (주)에스메디 2-아릴벤조싸이오펜 유도체 또는 이의 약학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 퇴행성 뇌질환의 진단 또는 치료용 약학적 조성물
CN102470127A (zh) 2009-08-19 2012-05-23 埃姆比特生物科学公司 联芳基化合物和其使用方法
AU2010351938B2 (en) 2010-04-27 2014-10-30 Hutchison Medipharma Limited Pyrimidinyl indole compounds
EP2694707B1 (en) 2011-04-07 2018-08-15 Cornell University Monomers capable of dimerizing in an aqueous solution, and methods of using same
US9245773B2 (en) 2011-09-02 2016-01-26 Taiwan Semiconductor Manufacturing Company, Ltd. Semiconductor device packaging methods and structures thereof
CN103159742B (zh) * 2011-12-16 2015-08-12 北京韩美药品有限公司 5-氯嘧啶类化合物及其作为egfr酪氨酸激酶抑制剂的应用
JP6250561B2 (ja) * 2012-02-08 2017-12-20 サノビオン ファーマシューティカルズ インクSunovion Pharmaceuticals Inc. ヘテロアリール化合物およびそれらの使用方法
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
JO3805B1 (ar) 2013-10-10 2021-01-31 Araxes Pharma Llc مثبطات كراس جي12سي
CN105085434B (zh) * 2014-05-09 2018-02-09 上海特化医药科技有限公司 硫乙拉嗪或其中间体的制备方法
WO2017076888A1 (en) * 2015-11-03 2017-05-11 Janssen Pharmaceutica Nv 2-[3-(1-methyl-piperidin-4-yl)-propylamino]-pyrimidine-5-carboxylic acids and amides and methods of making the same
JP7187437B2 (ja) 2016-07-29 2022-12-12 サノビオン ファーマシューティカルズ インク 化合物および組成物ならびにそれらの使用
EP3490607A4 (en) 2016-07-29 2020-04-08 Sunovion Pharmaceuticals Inc. COMPOUNDS AND COMPOSITIONS, AND USES THEREOF
WO2018140514A1 (en) 2017-01-26 2018-08-02 Araxes Pharma Llc 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
US11274093B2 (en) 2017-01-26 2022-03-15 Araxes Pharma Llc Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
WO2018140599A1 (en) * 2017-01-26 2018-08-02 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
JP2020521740A (ja) 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー 変異体kras、hrasまたはnrasの調節因子としてのキナゾリン誘導体
TW201900633A (zh) 2017-05-25 2019-01-01 美商亞瑞克西斯製藥公司 Kras之共價抑制劑
SG11202000669VA (en) 2017-08-02 2020-02-27 Sunovion Pharmaceuticals Inc Isochroman compounds and uses thereof
US12134620B2 (en) 2018-08-01 2024-11-05 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
KR20210139376A (ko) 2019-03-14 2021-11-22 선오비온 파마슈티컬스 인코포레이티드 이소크로마닐 화합물의 염, 및 이의 결정성 형태, 제조방법, 치료 용도 및 약제학적 조성물

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989011279A1 (en) * 1988-05-16 1989-11-30 Georgia State University Foundation, Inc. Nucleic acid interacting unfused heteropolycyclic compounds
GB0308466D0 (en) * 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CN101115749B (zh) 2004-12-17 2011-06-22 安姆根有限公司 氨基嘧啶化合物和使用方法

Similar Documents

Publication Publication Date Title
JP2009516697A5 (enExample)
AR057911A1 (es) Compuestos de pirimidinil benzotiofeno formulacion farmaceutica que lo comprende y su uso para la manufactura de un medicamento
JP2013507425A5 (enExample)
JP2007508359A5 (enExample)
JP2007524696A5 (enExample)
JP2015522650A5 (enExample)
JP2016516043A5 (enExample)
PE20090290A1 (es) Derivados de pirrolopiridina como inhibidores de bace
JP2017511357A5 (enExample)
JP2008525417A5 (enExample)
JP2006524222A5 (enExample)
JP2011522866A5 (enExample)
JP2010504286A5 (enExample)
JP2013501720A5 (enExample)
JP2009530424A5 (enExample)
JP2009531376A5 (enExample)
JP2012528166A5 (enExample)
NO20072371L (no) Kinuklidinderivater og deres anvendelse som muskarine M3-reseptorantagonister
JP2005538100A5 (enExample)
JP2010535722A5 (enExample)
CR11207A (es) Compuestos organicos
JP2009533410A5 (enExample)
JP2010526814A5 (enExample)
JP2016513681A5 (enExample)
JP2012502099A5 (enExample)